{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:33:42Z","timestamp":1791614022043,"version":"4.3.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1038\/s41375-022-01752-5","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:03:34Z","timestamp":1668193414000},"page":"2931-2933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-2543","authenticated-orcid":false,"given":"Jeffrey D.","family":"Mandell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1940-393X","authenticated-orcid":false,"given":"J. Nick","family":"Fisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Cyrenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-245X","authenticated-orcid":false,"given":"Mina L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6364-7747","authenticated-orcid":false,"given":"Vincent L.","family":"Cannataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-3907","authenticated-orcid":false,"given":"Jeffrey P.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"1752_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/s41375-021-01242-0","volume":"35","author":"R Gunnarsson","year":"2021","unstructured":"Gunnarsson R, Yang M, Olsson-Arvidsson L, Biloglav A, Behrendtz M, Castor A, et al. Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing. Leukemia. 2021;35:1485\u20139.","journal-title":"Leukemia."},{"key":"1752_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","volume":"4","author":"S Al-Harbi","year":"2020","unstructured":"Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020;4:229\u201338.","journal-title":"Blood Adv"},{"key":"1752_CR3","doi-asserted-by":"publisher","unstructured":"Sillar JR, Germon ZP, DeIuliis GN, Dun MD. The role of reactive oxygen species in acute myeloid leukaemia. Int J Mol Sci. 2019;20, https:\/\/doi.org\/10.3390\/ijms20236003.","DOI":"10.3390\/ijms20236003"},{"key":"1752_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/jnci\/djy168","volume":"110","author":"VL Cannataro","year":"2018","unstructured":"Cannataro VL, Gaffney SG, Townsend JP. Effect Sizes of Somatic Mutations in Cancer. J Natl Cancer Inst. 2018;110:1171\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"1752_CR5","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41388-018-0657-6","volume":"38","author":"VL Cannataro","year":"2019","unstructured":"Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, et al. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene. 2019;38:3475\u201387.","journal-title":"Oncogene."},{"key":"1752_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101.","journal-title":"Nature."},{"key":"1752_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0539-0","volume":"10","author":"F Blokzijl","year":"2018","unstructured":"Blokzijl F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 2018;10:33.","journal-title":"Genome Med"},{"key":"1752_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11037-8","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, et al. A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019;10:2969.","journal-title":"Nat Commun"},{"key":"1752_CR9","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","DOI":"10.1056\/NEJMoa1301689"},{"key":"1752_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171:1029\u201341.e21.","journal-title":"Cell."},{"key":"1752_CR11","doi-asserted-by":"publisher","unstructured":"Cannataro VL, Mandell JD, Townsend JP. Attribution of cancer origins to endogenous, exogenous, and preventable mutational processes. Mol Biol Evol. 2022;39, https:\/\/doi.org\/10.1093\/molbev\/msac084.","DOI":"10.1093\/molbev\/msac084"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01752-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:12:46Z","timestamp":1669795966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01752-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1752"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01752-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JPT has consulted for Black Diamond Therapeutics, Agios Pharmaceuticals, and Servier Pharmaceuticals. VLC has consulted for Black Diamond Therapeutics. MLX has consulted for Blueprint Medicines and Pure Marrow and has served on the advisory board for Seattle Genetics. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}